Epidemiologic Registry PETHEMA LMA 2013

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

NCT06459024 ·Status: RECRUITING

Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years

NCT00464217 ·Status: COMPLETED ·Phase: PHASE4

Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

NCT04777916 ·Status: RECRUITING

Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

NCT04460950 ·Status: RECRUITING

Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

NCT04589728 ·Status: COMPLETED

ObServatory Children Acute RElated Therapy Leukemia

NCT04450784 ·Status: UNKNOWN

Assessing Refractoriness and Infectious Survival Events in AML

NCT06709235 ·Status: COMPLETED

Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

NCT05048615 ·Status: COMPLETED ·Phase: PHASE2

De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients

NCT06557421 ·Status: RECRUITING ·Phase: PHASE2

Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma Concentrations

NCT07254611 ·Status: COMPLETED

Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital

NCT05558943 ·Status: NOT_YET_RECRUITING

GITMO AML/MDS-Relapse Registry Study

NCT06790680 ·Status: COMPLETED

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project

NCT01252485 ·Status: RECRUITING

Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia

NCT02986620 ·Status: COMPLETED

Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.

NCT03311815 ·Status: COMPLETED

Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments

NCT06764459 ·Status: RECRUITING

Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy

NCT06891144 ·Status: RECRUITING

A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML

NCT06014489 ·Status: RECRUITING ·Phase: PHASE2

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

NCT06696183 ·Status: RECRUITING ·Phase: PHASE2

Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain

NCT03435341 ·Status: COMPLETED

Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML

NCT05654194 ·Status: UNKNOWN ·Phase: PHASE3

Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies

NCT05772559 ·Status: RECRUITING

Epidemiology of Infection in Acute Myeloid Leukemia (AML)

NCT06797648 ·Status: NOT_YET_RECRUITING

DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US

NCT02863458 ·Status: WITHDRAWN

Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult

NCT06285136 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3